MetaCap

Eton Pharmaceuticals Inc. (ETON)

NASDAQ: ETONHealth CareBiotechnology: Pharmaceutical PreparationsUSD

60.85-0.51 (-0.83%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ETON stock chart

Technical analysis

Key statistics

All statistics
52-week range
14.27 – 70.64
Day range
59.18 – 61.65
Volume / Avg
562.53K / 570.79K
Beta
—

52-week range

$14.27$70.64

ETON stock today

Shares of Eton Pharmaceuticals (ETON) finished lower on Nov 20 at $60.85, a drop of 0.83% or $0.51 per share, versus the S&P 500's 3.70% decline. At this level, ETON sits near the top of its 52-week range of $14.27 to $70.64: 13.9% below the high, set on Nov 11, 2026 and 326.4% above the low. ETON is up 259.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 269.7%.

Eton Pharmaceuticals trades at 39.5x its trailing twelve-month earnings per share of $1.54. Its forward P/E of 18.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Eton Pharmaceuticals

Company profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Sean E. Brynjelsen
Headquarters
Deer Park, IL
Employees
44
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Eton Pharmaceuticals generated $80.0 million in revenue, up 104.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Eton Pharmaceuticals reported a net loss of $4.6 million, compared with a loss of $3.8 million a year earlier. Gross margin was 53.5% (down from 60.0%) and operating margin -1.1%.

Eton Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$79.95M$39.01M$31.64M$21.25M$21.83M
Growth+104.94%+23.29%+48.90%-2.66%+55879.49%
Net income$-4.60M$-3.82M$-936.00K$-9.02M$-1.96M
EPS (diluted)————$-0.08

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$80.75+32.70%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $80.00High $82.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$1.06 vs $0.34
Surprise
+211.76%

ETON news

All ETON news

Eton Pharmaceuticals peers

Health Care sector
ETON peer companies
CompanyPrice% ChgMarket capCompare
STOKStoke Therapeutics Inc.26.81-0.45%$1.75Bvs ETON
TRAXFirst Tracks Biotherapeutics Inc.41.64-6.34%$1.75Bvs ETON
ZYMEZymeworks Inc.26.14-2.68%$1.81Bvs ETON
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs ETON
SDGRSchrodinger Inc.22.93-12.95%$1.72Bvs ETON
KRSAKorsana Biosciences Inc.37.56+5.95%$1.71Bvs ETON
SEPNSepterna Inc.38.61-1.51%$1.84Bvs ETON
VERAVera Therapeutics Inc. Class A25.45-4.86%$1.84Bvs ETON

Indexes, lists and sector

Eton Pharmaceuticals stock FAQ

What is Eton Pharmaceuticals's stock price today?

ETON last traded at $60.85 as of Nov 20, 4:00 PM EST, down 0.83% on the day. Prices are delayed at least 15 minutes.

What is ETON's P/E ratio?

ETON trades at a trailing P/E ratio of 39.51 and a forward P/E of 18.41.

Who is Eton Pharmaceuticals's CEO?

Mr. Sean E. Brynjelsen is the chief executive officer of Eton Pharmaceuticals Inc., which has about 44 employees.

What is the ETON 52-week high?

The 52-week high for ETON is $70.64 and the 52-week low is $14.27. The stock is currently 13.9% below its high.

Compare ETON